4.8 Letter

Comment on Platelet-Derived Nucleotides Promote Tumor Cell Transendothelial Migration and Metastasis via P2Y2 Receptor by Schumacher et al.

Journal

CANCER CELL
Volume 24, Issue 3, Pages 287-287

Publisher

CELL PRESS
DOI: 10.1016/j.ccr.2013.08.016

Keywords

-

Funding

  1. British Heart Foundation [RG/10/006/28299] Funding Source: researchfish
  2. British Heart Foundation [RG/10/006/28299] Funding Source: Medline

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Cardiac & Cardiovascular Systems

Epigenetic Regulation of F2RL3 Associates With Myocardial Infarction and Platelet Function

Laura J. Corbin, Stephen J. White, Amy E. Taylor, Christopher M. Williams, Kurt Taylor, Marion T. van den Bosch, Jack E. Teasdale, Matthew Jones, Mark Bond, Matthew T. Harper, Louise Falk, Alix Groom, Georgina G. J. Hazell, Lavinia Paternoster, Marcus R. Munafo, Borge G. Nordestgaard, Anne Tybjaerg-Hansen, Stig E. Bojesen, Caroline Relton, Josine L. Min, George Davey Smith, Andrew D. Mumford, Alastair W. Poole, Nicholas J. Timpson

Summary: Epigenetic DNA hypomethylation at the F2RL3 gene induced by smoking may increase PAR4 expression, leading to downstream effects on platelet reactivity. F2RL3 DNA methylation may be a possible contributory pathway from smoking to cardiovascular disease risk.

CIRCULATION RESEARCH (2022)

Article Hematology

Maintaining flippase activity in procoagulant platelets is a novel approach to reducing thrombin generation

Sarah L. Millington-Burgess, Matthew T. Harper

Summary: The study revealed that R5421 can reduce platelet PS exposure and inhibit thrombin generation by maintaining flippase activity in procoagulant platelets, without directly inhibiting scramblase activity.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2022)

Article Cell Biology

Q94 is not a selective modulator of proteinase-activated receptor 1 (PAR1) in platelets

Luc R. A. Francis, Sarah L. Millington-Burgess, Taufiq Rahman, Matthew T. Harper

Summary: Thrombin activates platelets through PAR1 and PAR4, with PAR1 being the more rapidly activated receptor. Q94, an allosteric modulator of PAR1, has been reported to inhibit PAR1-G alpha q coupling in various cell lines, but its effects on human platelet activation have not been studied. Our data suggest that Q94 may have off-target effects in platelets independent of PAR1, precluding its use as a selective PAR1 allosteric modulator.

PLATELETS (2022)

Article Medicine, Research & Experimental

Clinical trial management: a profession in crisis?

E. J. Mitchell, K. Goodman, N. Wakefield, C. Cochran, S. Cockayne, S. Connolly, R. Desai, S. Hartley, S. A. Lawton, K. Oatey, S. Rhodes, J. S. Savage, J. Taylor, N. F. J. Youssouf

Summary: Clinical trial managers play a vital role in the design and conduct of clinical trials in the UK. However, there is currently a crisis in recruitment and retention for this role, which may have been exacerbated by the COVID-19 pandemic. This article presents the issues and suggests ways in which national stakeholders can address this problem.

TRIALS (2022)

Article Medicine, General & Internal

Selumetinib in combination with dexamethasone for the treatment of relapsed/refractory RAS-pathway mutated paediatric and adult acute lymphoblastic leukaemia (SeluDex): study protocol for an international, parallel-group, dose-finding with expansion phase I/II trial

Tobias Menne, Daniel Slade, Joshua Savage, Sarah Johnson, Julie Irving, Pamela Kearns, Ruth Plummer, Geoff Shenton, Gareth J. Veal, Britta Vormoor, Josef Vormoor, Lucinda Billingham

Summary: The study aims to evaluate the combination of selumetinib and dexamethasone in adult and paediatric patients with relapsed/refractory RAS pathway mutant ALL. The research will be conducted in multiple countries and results will be disseminated through national and international conferences and peer-reviewed publications.

BMJ OPEN (2022)

Article Health Care Sciences & Services

Subgroup analyses in randomized controlled trials frequently categorized continuous subgroup information

S. Faye Williamson, Michael J. Grayling, Adrian P. Mander, Nurulamin M. Noor, Joshua S. Savage, Christina Yap, James M. S. Wason

Summary: This study investigated the methods of subgroup analyses using continuous variables in published randomized controlled trials (RCTs). The results showed that the majority of studies dichotomized the continuous variables and treated the subgroups as categorical variables, potentially resulting in a loss of substantial statistical information.

JOURNAL OF CLINICAL EPIDEMIOLOGY (2022)

Article Medicine, Research & Experimental

Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units

Sharon B. Love, Fay Cafferty, Claire Snowdon, Karen Carty, Joshua Savage, Philip Pallmann, Lucy McParland, Louise Brown, Lindsey Masters, Francesca Schiavone, Dominic Hague, Stephen Townsend, Claire Amos, Annabelle South, Kate Sturgeon, Ruth Langley, Timothy Maughan, Nicholas James, Emma Hall, Sarah Kernaghan, Judith Bliss, Nick Turner, Andrew Tutt, Christina Yap, Charlotte Firth, Anthony Kong, Hisham Mehanna, Colin Watts, Robert Hills, Ian Thomas, Mhairi Copland, Sue Bell, David Sebag-Montefiore, Robert Jones, Mahesh K. B. Parmar, Matthew R. Sydes

Summary: This study summarizes the experience of running multiple successful late-phase platform protocols and provides recommendations and guidance. The recommendations cover the entire lifecycle of platform trials, including protocol development, funding acquisition, trial set-up, operational and regulatory aspects, result reporting, and communication with participants and stakeholders.

TRIALS (2022)

Article Medicine, General & Internal

Protocol for the Tessa Jowell BRAIN MATRIX Platform Study

Colin Watts, Joshua Savage, Amit Patel, Rhys Mant, Victoria Wykes, Ute Pohl, Helen Bulbeck, John Apps, Rowena Sharpe, Gerard Thompson, Adam D. Waldman, Olaf Ansorge, Lucinda Billingham

Summary: This study aims to improve the understanding and treatment of gliomas by collecting clinical, imaging, and pathology data from secondary care hospitals to establish a data repository. The study will use methods such as whole-genome sequencing and epigenomic classification to diagnose gliomas and investigate other measures related to gliomas. The target recruitment for this study is 1000 patients.

BMJ OPEN (2022)

Letter Hematology

Platelet procoagulant membrane dynamics: a key distinction between thrombosis and hemostasis?

Ejaife O. Agbani, Ingeborg Hers, Alastair W. Poole

BLOOD ADVANCES (2023)

Letter Hematology

Chemical degradation of BTK/TEC as a novel approach to inhibit platelet function

Justin S. Trory, Attila Munkacsi, Kamila M. Sledz, Jordan Vautrinot, Lucy J. Goudswaard, Molly L. Jackson, Kate J. Heesom, Samantha F. Moore, Alastair W. Poole, Behnam Nabet, Varinder K. Aggarwal, Ingeborg Hers

BLOOD ADVANCES (2023)

Article Multidisciplinary Sciences

Human soluble CD39 displays substrate inhibition in a substrate-specific manner

Venkat M. K. Vadlamani, Kavinda K. J. Gunasinghe, Xavier W. Chee, Taufiq Rahman, Matthew T. Harper

Summary: CD39 is a key regulator that metabolizes extracellular ATP and ADP to AMP. This study demonstrates that soluble, recombinant CD39 exhibits substrate inhibition with ADP or ATP as the substrate. High concentrations of ATP or ADP significantly reduce CD39 activity. In contrast, inhibition is not observed with UDP or UTP as substrates. Understanding the substrate inhibition of CD39 is important for interpreting CD39 activity studies and investigations into drugs modulating CD39 activity.

SCIENTIFIC REPORTS (2023)

Article Multidisciplinary Sciences

Highly efficient platelet generation in lung vasculature reproduced by microfluidics

Xiaojuan Zhao, Dominic Alibhai, Tony G. Walsh, Nathalie Tarassova, Maximilian Englert, Semra Z. Birol, Yong Li, Christopher M. Williams, Chris R. Neal, Philipp Burkard, Stephen J. Cross, Elizabeth W. Aitken, Amie K. Waller, Jose Ballester Beltran, Peter W. Gunning, Edna C. Hardeman, Ejaife O. Agbani, Bernhard Nieswandt, Ingeborg Hers, Cedric Ghevaert, Alastair W. Poole

Summary: Perfusion of megakaryocytes through the mouse lung vasculature generates a large number of functional platelets. This study reveals the mechanisms of thrombopoiesis in lung vasculature and provides insights for large-scale platelet generation.

NATURE COMMUNICATIONS (2023)

Article Hematology

Consensus report on markers to distinguish procoagulant platelets from apoptotic platelets: communication from the Scientific and Standardization Committee of the ISTH

Emma C. Josefsson, Sofia Ramstrom, Johannes Thaler, Marie Lordkipanidze, COAGAPO Study Grp

Summary: The study aimed to identify a set of markers and/or methods to detect and distinguish procoagulant platelets from apoptotic platelets. Using flow cytometry, a combination of three surface markers, including P-selectin (CD62P), phosphatidylserine (recognized by annexin V), and platelet-specific receptor GPIX (CD42a) or αIIb integrin (CD41, GPIIb), was recommended for differentiation. Procoagulant platelets are positive for all three markers, while apoptotic platelets are positive for annexin V and platelet-specific surface receptor(s) but negative for P-selectin.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

Article Hematology

Alterations in platelet proteome signature and impaired platelet integrin & alpha;IIb & beta;3 activation in patients with COVID-19

Lucy J. Goudswaard, Christopher M. Williams, Jawad Khalil, Kate L. Burley, Fergus Hamilton, David Arnold, Alice Milne, Phil A. Lewis, Kate J. Heesom, Stuart J. Mundell, Andrew D. Davidson, Alastair W. Poole, Ingeborg Hers

Summary: Patients with COVID-19 have altered platelet function, which is associated with increased risk of thrombosis. Platelet protein expression is different in COVID-19 patients, and platelet functional responses are reduced. Platelets in COVID-19 patients also show increased association with neutrophils. These findings suggest that platelet-driven thromboinflammation may contribute to the increased risk of thrombosis in COVID-19 patients.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2023)

Article Hematology

Protease-activated receptor antagonists prevent thrombosis when dual antiplatelet therapy is insufficient in an occlusive thrombosis microfluidic model

Jess Berry, Matthew T. Harper

Summary: This study investigated the potential of protease-activated receptor (PAR) antagonists to prevent occlusive thrombosis under conditions where dual antiplatelet therapy (DAPT) is insufficient. The results showed that DAPT had limited efficacy when tissue factor (TF) was present, but combining DAPT with PAR antagonism was effective in preventing occlusive thrombosis.

RESEARCH AND PRACTICE IN THROMBOSIS AND HAEMOSTASIS (2022)

No Data Available